Press releases

Disruptive Pharma AB (publ) ("Disruptive Pharma" or the "Company") today announced that it has entered into an agreement to sell the GTX platform to a wholly owned subsidiary of Aurelia Invest AB ("Aurelia"). The transaction is the result of the process initiated in June 2026 to evaluate strategic alternatives for the GTX platform, which was...

Disruptive Pharma AB (publ), formerly Guard Therapeutics International AB (publ), (“Disruptive Pharma” or the “Company”) will ring the opening bell at Nasdaq Stockholm on 21 August 2026. On the same day, the Company’s shares will begin trading under the new ticker symbol DPHA, replacing GUARD. The bell-ringing ceremony marks the...

27 July 2026 – Guard Therapeutics International AB (publ) (to be renamed Disruptive Pharma AB (publ)) ("Guard Therapeutics" or the "Company") today announces that the reverse takeover (RTO) of Disruptive Pharma Holding AB (publ) ("Disruptive Pharma"), pursuant to the agreement entered into and announced on 10 June 2026, has been completed...

Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") has today received conditional approval from Nasdaq Stockholm ("Nasdaq") for the continued listing of the Company's shares on Nasdaq First North Growth Market. The application for continued listing was submitted on 11 June 2026 as part of the implementation...

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that it has initiated a structured transaction process regarding the so-called GTX platform, consisting of therapeutic peptides based on the endogenous protein alpha-1-microglobulin (A1M), together with related intellectual property and...